MedTrace Logo

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

NCT05343377 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-04-25

No results posted yet for this study

Summary

This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years. To observe the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS rate, 2-year OS rate, and CR rate in newly diagnosed ENKTCL patients; and to clarify the prognostic stratification ability of PINK-cpgE compared with PINK-E

Conditions

  • Extranodal Natural Killer/T-cell Lymphoma

Interventions

DIAGNOSTIC_TEST

circulate free methylated EBV DNA

Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

Sponsors & Collaborators

  • Zhenjiang First People's Hospital

    collaborator OTHER

  • Changzhou First People's Hospital

    collaborator UNKNOWN

  • Changzhou Second People's Hospital

    collaborator UNKNOWN

  • Wuxi People's Hospital

    collaborator OTHER

  • Second Affiliated Hospital of Soochow University

    collaborator OTHER

  • The First Affiliated Hospital of Nantong University

    collaborator UNKNOWN

  • Huaian first people's hospital

    collaborator UNKNOWN

  • Yancheng First People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-06-01
Completion
2028-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343377 on ClinicalTrials.gov